Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the response rate in patients affected by
metastatic ovarian cancer, treated with NGR-hTNF plus doxorubicin. Safety will be established
by clinical and laboratory assessment according to NCI-CTC criteria.